These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35936024)

  • 1. Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.
    Staadegaard L; Rönn MM; Soni N; Bellerose ME; Bloem P; Brisson M; Maheu-Giroux M; Barnabas RV; Drolet M; Mayaud P; Dalal S; Boily MC
    EClinicalMedicine; 2022 Oct; 52():101585. PubMed ID: 35936024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
    Stanley M; Joura E; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Brown DR
    Vaccine; 2021 Apr; 39(16):2214-2223. PubMed ID: 33658126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.
    Mavundza EJ; Wiyeh AB; Mahasha PW; Halle-Ekane G; Wiysonge CS
    Hum Vaccin Immunother; 2020; 16(2):426-435. PubMed ID: 31448991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.
    Kamolratanakul S; Pitisuttithum P
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy.
    Nakalembe M; Mirembe FM; Banura C
    Infect Agent Cancer; 2015; 10():17. PubMed ID: 26075018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
    Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
    Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
    Watson-Jones D; Changalucha J; Whitworth H; Pinto L; Mutani P; Indangasi J; Kemp T; Hashim R; Kamala B; Wiggins R; Songoro T; Connor N; Mbwanji G; Pavon MA; Lowe B; Mmbando D; Kapiga S; Mayaud P; de SanJosé S; Dillner J; Hayes RJ; Lacey CJ; Baisley K
    Lancet Glob Health; 2022 Oct; 10(10):e1473-e1484. PubMed ID: 36113531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
    Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
    Tunis MC; Deeks SL;
    Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.